Further validation is required regarding the synergistic effects of pemafibrate in combination with antidiabetic agents with potential effects on MASLD, such as SGLT2‐Is and GLP‐1 RAs, which were commonly used for type 2 diabetes mellitus in this population. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.